Adaptive Biotechnologies ADPT Ratios & Valuation
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 75.3%+12.7pp | 74.2%+14.5pp | 71.8%+13.4pp | 66%+11.3pp | 62.5%+5.5pp | |
| Operating margin | -15.8%+59.8pp | -20.6%+70.2pp | -30.9%+81.8pp | -59%+70.2pp | -75.7%+49.6pp | |
| Net margin | -16.8%+58.0pp | -21.5%+67.6pp | -31.5%+78.6pp | -59.1%+67.4pp | -74.8%+48.4pp | |
| EBITDA margin | -10.1%+55.7pp | -14.2%+65.9pp | -23.8%+77.5pp | -50.1%+66.5pp | -65.8%+46.9pp | |
| Free cash flow margin | -10.5%+36.4pp | -18.2%+37.1pp | -24.9%+39.7pp | -40.4%+40.6pp | -46.8%+36.2pp | |
| Returns | ||||||
| Return on equity | -24.4%+36.5pp | -28.2%+34.2pp | -37.2%+29.5pp | -57.5%+9.4pp | -61%+0.6pp | |
| Return on assets | -9.8%+15.3pp | -11.3%+15.3pp | -15.2%+15.4pp | -22.4%+9.2pp | -25.1%+5.4pp | |
| Return on invested capital | -13.2%+23.0pp | -15.5%+22.7pp | -20.2%+23.5pp | -31.8%+22.9pp | -36.2%+14.2pp | |
| Efficiency | ||||||
| Asset turnover | 0.6×+0.2× | 0.5×+0.2× | 0.5×+0.2× | 0.4×+0.1× | 0.3×+0.1× | |
| Inventory turnover | 7.3×+0.9× | 7.8×+1.5× | 6.5×+1.8× | 6.4×+1.7× | 6.5×+1.9× | |
| Liquidity | ||||||
| Current ratio | 3.4×+0.4× | 3.3×+0.4× | 3.4×-0.1× | 2.8×-1.1× | 2.9×-1.6× | |
| Quick ratio | 3.2×+0.4× | 3.2×+0.4× | 3.3×-0.1× | 2.8×-1.1× | 2.8×-1.5× | |
| Cash ratio | 0.9×+0.3× | 0.8×+0.3× | 0.7×+0.2× | 0.5×-0.2× | 0.6×-0.3× | |
| Leverage | ||||||
| Debt-to-equity | 1×-0.2× | 1×-0.1× | 1×0.0× | 1.2×+0.3× | 1.2×+0.3× | |
| Debt-to-assets | 0.4×0.0× | 0.4×0.0× | 0.4×0.0× | 0.4×+0.1× | 0.4×+0.1× | |
| Interest coverage | -4×+8.5× | -4.9×+9.2× | -6.6×+10.5× | -10.3×+7.3× | -12.5×+4.0× | |
| Per Share | ||||||
| Book value per share | $1.39+9.0% | $1.44+4.7% | $1.25-17.4% | $1.18-27.9% | $1.28-32.3% | |
| Valuation | ||||||
| Market capitalization | $2.14B+93.6% | $2.48B+180% | $2.28B+202% | $1.62B+203% | $1.1B+137% | |
| Enterprise value | $2.27B+78.0% | $2.62B+147% | $2.44B+159% | $1.79B+156% | $1.27B+105% | |
| Price / sales | 7.2×+1.4× | 9×+4.0× | 9×+4.8× | 7.9×+4.7× | 5.8×+3.2× | |
| Price / book | 9.9×+4.1× | 11.3×+7.0× | 11.1×+7.8× | 9×+6.8× | 5.8×+4.1× | |
| EV / sales | 7.7×+1.0× | 9.5×+3.5× | 9.6×+4.3× | 8.7×+4.6× | 6.7×+3.2× | |
| Free cash flow yield | -1.4%+6.6pp | -2%+9.1pp | -2.8%+12.4pp | -5.1%+20.5pp | -8%+23.1pp | |
| Earnings yield | -2.3%+10.5pp | -2.4%+15.6pp | -3.5%+22.4pp | -7.5%+32.5pp | -12.8%+33.3pp |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Adaptive Biotechnologies's profit margins?
- Adaptive Biotechnologies (ADPT) runs a 75.3% gross margin and a -15.8% operating margin, with a -16.8% net margin.
- Where do Adaptive Biotechnologies's ratios come from?
- Every ratio is computed from Adaptive Biotechnologies's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
